Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CV Therapeutics
Ranolazine study demonstrates important cardiac ion channel effects
September 24th, 2004
In a recent preclinical study, researchers concluded that potentially antiarrhythmic effects observed with ranolazine may be due to the ability of ranolazine to inhibit the late sodium current. The effect of ranolazine on the late sodium current could be relevant to the drug's potential to treat a variety of cardiovascular conditions, including chronic angina and acute coronary syndromes (ACS). The research team, led by Charles Antzelevitch, PhD, executive director and director of research at Masonic Medical Laboratory in Utica, New York, recorded the effects of ranolazine on ion current channels in animal heart cells at drug concentrations ranging...
Source: Food & Drug Law Weekly (2004-09-24)
|
